199 related articles for article (PubMed ID: 8952866)
1. Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Milani M; Cimminiello C; Lorena M; Arpaia G; Soncini M; Bonfardeci G
Biomed Pharmacother; 1996; 50(6-7):269-74. PubMed ID: 8952866
[TBL] [Abstract][Full Text] [Related]
2. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
[TBL] [Abstract][Full Text] [Related]
3. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
Romano M; Mezzetti A; Marulli C; Ciabattoni G; Febo F; Di Ienno S; Roccaforte S; Vigneri S; Nubile G; Milani M; Davì G
J Investig Med; 2000 May; 48(3):183-9. PubMed ID: 10822898
[TBL] [Abstract][Full Text] [Related]
4. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
[TBL] [Abstract][Full Text] [Related]
5. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
7. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
8. Increased thromboxane metabolites excretion in liver cirrhosis.
Davì G; Ferro D; Basili S; Iuliano L; Camastra C; Giammarresi C; Santarone S; Rocca B; Landolfi R; Ciabattoni G; Cordova C; Violi F
Thromb Haemost; 1998 Apr; 79(4):747-51. PubMed ID: 9569186
[TBL] [Abstract][Full Text] [Related]
9. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
[TBL] [Abstract][Full Text] [Related]
10. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
11. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
12. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Branchi A; Rovellini A; Fiorenza AM; Sommariva D
Int J Clin Pharmacol Ther; 1995 Jun; 33(6):345-50. PubMed ID: 7582386
[TBL] [Abstract][Full Text] [Related]
13. Increased thromboxane biosynthesis in essential thrombocythemia.
Rocca B; Ciabattoni G; Tartaglione R; Cortelazzo S; Barbui T; Patrono C; Landolfi R
Thromb Haemost; 1995 Nov; 74(5):1225-30. PubMed ID: 8607099
[TBL] [Abstract][Full Text] [Related]
14. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
Saxenhofer H; Weidmann P
Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
[TBL] [Abstract][Full Text] [Related]
15. Fluvastatin prevents renal injury and expression of lactin-like oxidized low-density lipoprotein receptor-1 in rabbits with hypercholesterolemia.
Yu YH; Wang Y; Dong B; Sun SZ; Chen Y; Meng XH; Liu ZZ
Chin Med J (Engl); 2005 Apr; 118(8):621-6. PubMed ID: 15899115
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage.
Saloheimo P; Juvela S; Riutta A; Pyhtinen J; Hillbom M
Thromb Res; 2005; 115(5):367-73. PubMed ID: 15733969
[TBL] [Abstract][Full Text] [Related]
17. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
18. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
19. Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia.
Lee WJ; Lee WL; Tang YJ; Liang KW; Chien YH; Tsou SS; Sheu WH
Clin Chim Acta; 2008 Apr; 390(1-2):49-55. PubMed ID: 18201563
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
Schrör K; Löbel P; Steinhagen-Thiessen E
Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]